Glenn Liu, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
Dr. Liu joined the faculty as an Assistant Professor of Medicine at the University of Wisconsin in 2003, where he currently specializes in genitourinary oncology and experimental therapeutics. Previously, Dr. Liu did his undergraduate training at Dartmouth College, where he majored in biochemical engineering. From there, he received his Master's Degree at Boston University before obtaining his MD at Jefferson Medical College. Dr. Liu completed his internal medicine and oncology training at the University of Wisconsin Hospital and Clinics, with additional training in genitourinary oncology as part of a K12 grant at the University of Wisconsin Carbone Cancer Center.
UW Health Clinics
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
UW Comprehensive Cancer Center
University of Wisconsin Hospital and Clinics, Madison, WI
University of Wisconsin Hospital and Clinics, Madison, WI
Thomas Jefferson Medical College, Philadelphia, PA, 1997
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
Our doctors provide a wide range of services. The following list represents some, but not all, of the procedures offered by this physician.
Dr. Liu specializes in the treatment of all genitourinary cancers and is a recognized clinical researcher as evident by his service on the Eastern Cooperative Oncology Group (ECOG) Genitourinary Oncology Core Committee as the Genitourinary (GU) Liaison for the ECOG Developmental Therapeutics Committee, for which he is also a member. He currently serves as the disease group leader for the GU Oncology Disease Group, a NCI-designated Phase II Consortium, and thus is highly active in local, regional, and national trials in all stages of development. Dr. Liu is also a member of the experimental therapeutics (Phase I) program at the UW Carbone Cancer Center, and thus is involved in early drug development.
Smith MR Antonarakis ES Ryan CJ Berry WR Shore ND Liu G Alumkal JJ Higano CS Chow Maneval E Bandekar R de Boer CJ Yu MK Rathkopf DE .
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 May 5;
[PubMed ID: 27160947]
Scher HI Morris MJ Stadler WM Higano C Basch E Fizazi K Antonarakis ES Beer TM Carducci MA Chi KN Corn PG de Bono JS Dreicer R George DJ Heath EI Hussain M Kelly WK Liu G Logothetis C Nanus D Stein MN Rathkopf DE Slovin SF Ryan CJ Sartor O Small EJ Smith MR Sternberg CN Taplin ME Wilding G Nelson PS Schwartz LH Halabi S Kantoff PW Armstrong AJ .
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20;34(12):1402-18
[PubMed ID: 26903579]
Kyriakopoulos CE Heath EI Eickhoff JC Kolesar J Yayehyirad M Moll T Wilding G Liu G .
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Invest New Drugs. 2016 Apr;34(2):225-30
[PubMed ID: 26924129]
Deming DA Cavalcante LL Lubner SJ Mulkerin DL LoConte NK Eickhoff JC Kolesar JM Fioravanti S Greten TF Compton K Doyle AG Wilding G Duffy A Liu G .
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest New Drugs. 2016 Apr;34(2):168-75
[PubMed ID: 26666244]
Wisinski KB Tevaarwerk AJ Burkard ME Rampurwala M Eickhoff J Bell MC Kolesar JM Flynn C Liu G .
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res. 2016 Mar 29;
[PubMed ID: 27026198]
Bruce JY LoRusso PM Goncalves PH Heath EI Sadowski E Shalinsky DR Zhang Y Traynor AM Breazna A Ricart AD Tortorici M Liu G .
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Mar;77(3):527-38
[PubMed ID: 26791870]
Stein MN Hussain M Stadler WM Liu G Tereshchenko IV Goodin S Jeyamohan C Kaufman HL Mehnert J DiPaola RS .
A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer. 2016 Feb;14(1):22-7
[PubMed ID: 26476589]
Thakur MK Heilbrun LK Sheng S Stein M Liu G Antonarakis ES Vaishampayan U Dzinic SH Li X Freeman S Smith D Heath EI .
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs. 2016 Feb;34(1):112-8
[PubMed ID: 26581400]
Luo H England CG Graves SA Sun H Liu G Nickles RJ Cai W .
PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab. J Nucl Med. 2016 Feb;57(2):285-90
[PubMed ID: 26541778]
Carducci MA Manola J Nair SG Liu G Rousey S Dutcher JP Wilding G .
Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800). Clin Genitourin Cancer. 2015 Dec;13(6):531-539.e1
[PubMed ID: 26272427]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH .
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract. 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Simoncic U Perlman S Liu G Jeraj R .
Optimizing an 18F-NaF and 18F-FDG cocktail for PET assessment of metastatic castration-resistant prostate cancer. Nucl Med Commun. 2015 Dec;36(12):1174-80
[PubMed ID: 26378490]
Hussain M Rathkopf D Liu G Armstrong A Kelly WK Ferrari A Hainsworth J Joshi A Hozak RR Yang L Schwartz JD Higano CS .
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015 Sep;51(13):1714-24
[PubMed ID: 26082390]
Sweeney CJ Chen YH Carducci M Liu G Jarrard DF Eisenberger M Wong YN Hahn N Kohli M Cooney MM Dreicer R Vogelzang NJ Picus J Shevrin D Hussain M Garcia JA DiPaola RS .
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20;373(8):737-46
[PubMed ID: 26244877]
Bruce JY Scully PC Carmichael LL Eickhoff JC Perlman SB Kolesar JM Heideman JL Jeraj R Liu G .
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography. Cancer Chemother Pharmacol. 2015 Jul;76(1):187-95
[PubMed ID: 26021741]
Wisinski KB Cantu CA Eickhoff J Osterby K Tevaarwerk AJ Heideman J Liu G Wilding G Johnston S Kolesar JM .
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. Am J Health Syst Pharm. 2015 Jun 1;72(11):958-65
[PubMed ID: 25987691]
Simoncic U Perlman S Liu G Staab MJ Straus JE Jeraj R .
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer. 2015 Feb;13(1):e7-e17
[PubMed ID: 25128349]
LoConte NK Razak AR Ivy P Tevaarwerk A Leverence R Kolesar J Siu L Lubner SJ Mulkerin DL Schelman WR Deming DA Holen KD Carmichael L Eickhoff J Liu G .
A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs. 2015 Feb;33(1):169-76
[PubMed ID: 25318436]
Muzahir S Jeraj R Liu G Hall LT Rio AM Perk T Jaskowiak C Perlman SB .
Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. Am J Nucl Med Mol Imaging. 2015;5(2):162-8
[PubMed ID: 25973337]
Lubner SJ Mullvain J Perlman S Pishvaian M Mortimer J Oliver K Heideman J Hall L Weichert J Liu G .
A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies. Cancer Invest. 2015;33(10):483-9
[PubMed ID: 26536061]